Benesch Joseph 4

What Happened
Joseph Benesch, Chief Financial Officer of Journey Medical Corp (DERM), received equity awards on April 22, 2026: 28,907 restricted stock units (RSUs) and 41,860 stock options. Both transactions are reported as awards (code A) with $0.00 cash paid at grant; the RSUs and options vest over three years per the footnotes.

Key Details

• Transaction date: April 22, 2026; Form 4 filed April 24, 2026 (appears timely).
• Awards: 28,907 RSUs (reported acquisition value $0.00) and 41,860 stock options (reported $0.00).
• Vesting schedule (per filing footnotes):
  • RSUs: 9,636 shares vest on Apr 22, 2027; 9,636 on Apr 22, 2028; 9,635 on Apr 22, 2029.
  • Options: 13,953 options vest on Apr 22, 2027; 13,953 on Apr 22, 2028; 13,954 on Apr 22, 2029.
• Post-transaction share ownership: not specified in the provided filing excerpt.
• Transaction codes: A = award/grant; includes derivative award (options) as noted.
• No indication in the filing that the awards were part of a 10b5-1 plan, a gift, or a cashless exercise.

Context
These are compensation grants—not purchases or sales. RSUs convert to shares upon vesting; options give the right to buy shares at their exercise price (exercise price not provided in the excerpt). Such grants are routine long-term incentive awards and do not, by themselves, represent a market purchase or sale.